IN2015DN03219A - - Google Patents

Info

Publication number
IN2015DN03219A
IN2015DN03219A IN3219DEN2015A IN2015DN03219A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A IN 3219DEN2015 A IN3219DEN2015 A IN 3219DEN2015A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A
Authority
IN
India
Prior art keywords
pridopidine
laquinimod
treating
neurodegenerative disorder
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Hayden
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2015DN03219A publication Critical patent/IN2015DN03219A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3219DEN2015 2012-09-27 2013-09-27 IN2015DN03219A (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US201361879004P 2013-09-17 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
IN2015DN03219A true IN2015DN03219A (uk) 2015-10-02

Family

ID=50339469

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3219DEN2015 IN2015DN03219A (uk) 2012-09-27 2013-09-27

Country Status (13)

Country Link
US (7) US20140088140A1 (uk)
EP (1) EP2900330A4 (uk)
CN (1) CN104902958A (uk)
AU (1) AU2013323131A1 (uk)
BR (1) BR112015006623A2 (uk)
CA (1) CA2884781A1 (uk)
EA (1) EA201590655A8 (uk)
HK (2) HK1211525A1 (uk)
IL (1) IL237742A0 (uk)
IN (1) IN2015DN03219A (uk)
MX (1) MX2015003608A (uk)
WO (1) WO2014052933A1 (uk)
ZA (1) ZA201502600B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2008127188A1 (en) * 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
ES2879631T3 (es) 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de la enfermedad de Huntington
CA2933380A1 (en) * 2013-12-20 2015-06-25 Esther Lukasiewicz Hagai Use of laquinimod to delay huntington's disease progression
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2961187A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceuticals Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
HUE060353T2 (hu) * 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CA3151507C (en) 2016-08-24 2024-05-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
FI3668509T3 (fi) 2017-08-14 2023-03-14 Prilenia Neurotherapeutics Ltd Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla
CA3128250C (en) * 2019-03-15 2024-01-16 Michael Hayden Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
MX2021015338A (es) * 2019-06-12 2022-01-18 Prilenia Neurotherapeutics Ltd Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528040T3 (es) * 2007-06-18 2015-02-03 A.Carlsson Research Ab Uso de estabilizadores de dopamina
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
JP5859438B2 (ja) * 2009-08-10 2016-02-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いたｂｄｎｆ関連疾患の治療
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
BR112013014061A2 (pt) * 2010-12-07 2016-09-13 Teva Pharma uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla

Also Published As

Publication number Publication date
HK1211525A1 (en) 2016-05-27
AU2013323131A1 (en) 2015-05-07
EA201590655A8 (ru) 2016-07-29
CA2884781A1 (en) 2014-04-03
CN104902958A (zh) 2015-09-09
WO2014052933A1 (en) 2014-04-03
EP2900330A1 (en) 2015-08-05
US20190117639A1 (en) 2019-04-25
US20180133209A1 (en) 2018-05-17
IL237742A0 (en) 2015-05-31
US20180369228A1 (en) 2018-12-27
US20140088140A1 (en) 2014-03-27
US20150209346A1 (en) 2015-07-30
ZA201502600B (en) 2016-06-29
HK1214553A1 (zh) 2016-07-29
EA201590655A1 (ru) 2015-12-30
MX2015003608A (es) 2015-06-05
US20170319569A1 (en) 2017-11-09
EP2900330A4 (en) 2016-05-25
BR112015006623A2 (pt) 2017-07-04
US20180250285A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
IN2015DN03219A (uk)
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MY166014A (en) Combination therapy methods for treating proliferative diseases
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
IN2013MU01155A (uk)
IN2013MU01252A (uk)
IN2013MU01154A (uk)
IN2013MU01246A (uk)
IN2013MU01244A (uk)